Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
US10071983B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10071983-B2 |
| Application number | US-201615131129-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2016 |
| Priority date | Mar 15, 2011 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes.
Opening claim text (preview).
What is claimed is: 1. A fluorogenic compound comprising three acceptor-containing moieties and a donor-containing moiety arranged such that: (i) said three acceptor-containing moieties and said donor-containing moiety form a conjugated π-electron system devoid of resonating electrons, such that the compound is incapable of emitting NIR infrared light; and (ii) upon a chemical event, said donor-containing moiety rearranges so as to transfer π-electrons to one of said acceptor-containing moieties and, as a result, said acceptor-containing moiety becomes a donor-containing moiety to the other acceptor-containing moieties, to thereby enable emission of near infrared light, wherein each of said acceptor-containing moieties is independently selected from an ammonium form of an indolenine or an ammonium form of a pyridine, and wherein said donor containing moiety comprises an aryl substituted by at least one electron-donating group, and is such that upon said chemical event, it rearranges by undergoing a quinonemethidine-like rearrangement, said donor-containing moiety being independently linked to each of said three acceptor-containing moieties either directly or via a linking moiety, said linking moiety comprising a carbomethine-containing chain of at least one —CR′═CR″— moiety, wherein R′ and R″ are each independently hydrogen, alkyl or cycloalkyl, or, alternatively, R′ and R″ form together an aryl, and is such that said acceptor-containing moieties and said donor containing moiety form said conjugated π-electron system. 2. The fluorogenic compound of claim 1 , wherein each of said acceptor-containing moieties is an ammonium form of an indolenine. 3. The fluorogenic compound of claim 1 , wherein each of said acceptor-containing moieties is an ammonium form of a pyridine. 4. The fluorogenic compound of claim 1 , wherein one of said acceptor-containing moieties is an ammonium form of an indolenine and another one of said acceptor-containing moieties is an ammonium form of a pyridine. 5. The fluorogenic compound of claim 1 , wherein said donor-containing moiety comprises phenyl substituted by hydroxy. 6. The fluorogenic compound of claim 1 , selected from: 7. The fluorogenic compound of claim 1 , wherein said chemical event is generated by an analyte. 8. The fluorogenic compound of claim 1 , wherein said chemical event comprises cleavage in said donor-containing moiety. 9. The fluorogenic compound of claim 1 , wherein said donor-containing moiety comprises a trigger unit, and wherein said chemical event comprises cleavage of said trigger unit. 10. The fluorogenic compound of claim 9 , wherein said cleavage of said trigger unit is effected in the presence of an analyte. 11. The compound of claim 7 , wherein said analyte is associated with a medical condition. 12. The compound of claim 11 , wherein said analyte is an enzyme overexpressed in organs or tissues afflicted by said medical condition. 13. The compound of claim 11 , wherein said analyte is a substance that is produced in organs or tissues in response to said medical condition. 14. The fluorogenic compound of claim 1 , further comprising a therapeutically active agent being attached to said donor-containing moiety. 15. The fluorogenic compound of claim 14 , wherein said therapeutically active agent is attached to said donor-containing moiety such that upon said chemical event, said therapeutically active agent is released. 16. A method of determining a presence and/or level of an analyte in a sample, the method comprising contacting the sample with the fluorogenic compound of claim 7 ; and collecting a light emitted from said sample, wherein a presence and/or level of said light is indicative of the presence and/or level of said analyte. 17. The method of claim 16 , wherein said light has a wavelength within a near infrared range. 18. The method of claim 16 , wherein said analyte is associated with a medical condition, and wherein determining a presence and/or level of said analyte is being for determining a presence or progression of said medical condition. 19. The method of claim 18 , wherein said analyte is an enzyme overexpressed in organs or tissues afflicted by said medical condition. 20. The method of claim 19 , wherein said analyte is produced in response to said medical condition. 21. A method of imaging a sample, the method comprising contacting the sample with the fluorogenic compound of claim 1 , and collecting a light emitted from said sample. 22. The method of claim 21 , wherein said light has a wavelength within a near infrared range. 23. A pharmaceutical composition comprising the fluorogenic compound of claim 1 and a pharmaceutically acceptable carrier. 24. The pharmaceutical composition of claim 23 , wherein said chemical event is generated by an analyte and wherein the composition is identified for use in determining a presence and/or level of said analyte in a sample.
Peptides, proteins, polyamino acids · CPC title
Oxygen atoms · CPC title
with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring · CPC title
to which a second hetero atom is attached (nitro radicals C07D213/61) · CPC title
Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.